EWTX
Edgewise Therapeutics, Inc. [EWTX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
EWTX Stock Summary
In the News
EWTX Financial details
Company Rating
-
Market Cap
1.52B
Income
-97.06M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
88
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-8.38
Forward P/E
-
PEG
-0.2
P/S
-
P/B
2.41
P/C
-
P/FCF
-8.17
Quick Ratio
17.73
Current Ratio
18.23
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.53
EPS next Y
-
EPS next Q
-
EPS this Y
441.38%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
14.63%
-
-
-
-
SMA20
-1.62%
SMA50
20.9%
SMA100
91.02%
Inst Own
-
Inst Trans
-
ROA
-27%
ROE
-26%
ROC
-0.35%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
5.12-20.69
52W High
+47.95%
52W Low
+491.8%
RSI
52.01
Rel Volume
0.72
Avg Volume
959.07K
Volume
690.83K
Perf Week
2.46%
Perf Month
2.81%
Perf Quarter
107.5%
Perf Half Y
101.7%
-
-
-
-
Beta
0.15
-
-
Volatility
0.98%, 0.94%
Prev Close
-1.17%
Price
29.59
Change
-1.37%
Company Profile
- Volume Average 959.07K
- Market Capitalization 1.52B
- Employee 88
- CEO Dr. Kevin Koch Ph.D.
- Headquarters Boulder,CO,US
- IPO Date 2021-03-26
-
Website
https://www.edgewisetx.com 
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
